(Albany, United States) As per DelveInsight’s assessment, globally, the Endometriosis pipeline constitutes 18+ key companies continuously working towards developing 25+ Endometriosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Endometriosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Endometriosis clinical trials studies, Endometriosis NDA approvals (if any), and product development activities comprising the technology, Endometriosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Endometriosis Pipeline treatment landscape of the report, click here @ Endometriosis Pipeline Outlook

 

Key Takeaways from the Endometriosis Pipeline Report

• DelveInsight’s Endometriosis Pipeline analysis depicts a robust space with 18+ active players working to develop 25+ pipeline treatment therapies.
• The leading Endometriosis Companies working in the market include ObsEva SA, Myovant Sciences, Dexa Medica Group, Ferring Pharmaceuticals, Merck Sharp & Dohme Corp, Bayer, BCI Pharma, Jiangsu HengRui Medicine Co., Ltd., Forendo Pharma, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Nippon Shinyaku, Celmatix, Camurus, Enteris BioPharma, Viramal, and others
• Promising Endometriosis Pipeline Therapies in the various stages of development include OG-6219, SN132D, Leuprolide Oral Tablet – 120 mg – QD- Treatment A, and others
• ObsEva is currently advancing linzagolix, a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries.
• Relugolix Combination Tablet consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the treatment of endometriosis and for the prevention of pregnancy. Phase III clinical program for endometriosis consisted of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2) of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis.

 

Endometriosis Overview

Endometriosis is a disease in which the endometrium (the tissue that lines the inside of the uterus or womb) is present outside of the uterus. Endometriosis most commonly occurs in the lower abdomen or pelvis, but it can appear anywhere in the body.

 

To explore more information on the latest breakthroughs in the Endometriosis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

 

Endometriosis Emerging Drugs Profile

• Linzagolix: ObsEva
• Relugolix: Myovant Sciences

 

Endometriosis Pipeline Therapeutics Assessment

There are approx. 18+ Endometriosis companies which are developing the therapies for Endometriosis. The Endometriosis companies which have their Endometriosis drug candidates in the most advanced stage, i.e. Phase III include, ObsEva.

 

Request a sample and discover the recent advances in Endometriosis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

 

Endometriosis Drugs and Companies

• OG-6219: Iqvia Pty Ltd
• SN132D: Spago Nanomedical AB
• Leuprolide Oral Tablet – 120 mg – QD- Treatment A: Enteris BioPharma Inc.

 

Endometriosis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Endometriosis Therapeutics Market include-

ObsEva SA, Myovant Sciences, Dexa Medica Group, Ferring Pharmaceuticals, Merck Sharp & Dohme Corp, Bayer, BCI Pharma, Jiangsu HengRui Medicine Co., Ltd., Forendo Pharma, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Nippon Shinyaku, Celmatix, Camurus, Enteris BioPharma, Viramal, and others

 

Dive deep into rich insights for drugs for Endometriosis Pipeline, click here for Endometriosis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

 

Scope of the Endometriosis Pipeline Report

• Coverage- Global
• Endometriosis Companies- ObsEva SA, Myovant Sciences, Dexa Medica Group, Ferring Pharmaceuticals, Merck Sharp & Dohme Corp, Bayer, BCI Pharma, Jiangsu HengRui Medicine Co., Ltd., Forendo Pharma, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Nippon Shinyaku, Celmatix, Camurus, Enteris BioPharma, Viramal, and others
• Endometriosis Pipeline Therapies- OG-6219, SN132D, Leuprolide Oral Tablet – 120 mg – QD- Treatment A, and others.
• Endometriosis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Endometriosis Merger and acquisitions, and Licensing Activities @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Endometriosis Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Linzagolix: ObsEva
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Quinagolide: Ferring Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. BOL-DP-o-08: Breath of Life International Pharma Ltd
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Endometriosis Key Companies
17. Endometriosis Key Products
18. Endometriosis- Unmet Needs
19. Endometriosis- Market Drivers and Barriers
20. Endometriosis- Future Perspectives and Conclusion
21. Endometriosis Analyst Views
22. Endometriosis Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services